[125I]CGP 42112 reveals a non-angiotensin II binding site in 1-methyl-4-phenylpyridine (MPP+)-induced brain injury |
| |
| Authors: | M. Viswanathan A. M. de Oliverira R. -M. Wu C. C. Chiueh J. M. Saavedra |
| |
| Affiliation: | (1) Section on Pharmacology, Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, 20892 Bethesda, Maryland;(2) Unit of Neurotoxicology and Neuroprotection, Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, 20892 Bethesda, Maryland |
| |
| Abstract: | Summary 1. Intracerebral injection of the oxidative metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridine (MPP+), into the substantia nigra of adult rats resulted in a lesion at the injection site.2. Using autoradiography, we localized specific [125]CGP 42112 binding that was not recognized by angiostensin II or angiotensin II AT1 or AT2 receptorselective ligands.3. Our results suggest that [125I]CGP 42112 may be binding to activated microglia that appear at the lesion site. |
| |
| Keywords: | CGP 42112 1-methyl-4-phenylpyridine brain injury |
| 本文献已被 SpringerLink 等数据库收录！ |
|
